SOURCE: Actinium Pharmaceuticals

Actinium Pharmaceuticals

March 11, 2016 08:00 ET

Actinium Pharmaceuticals to Present at the 23rd Annual BioCentury Future Leaders in the Biotech Industry Conference

Company Presentation Scheduled for Friday, March 11, 2016 at 8:30 AM ET

NEW YORK, NY--(Marketwired - March 11, 2016) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers announced today that it will be presenting at the 23rd Annual BioCentury Future Leaders in the Biotech Industry Conference being held Friday, March 11, 2016 in New York. Actinium's Executive Chairman, Sandesh Seth, will present a corporate overview of the Company.

The conference is being held at the Millennium Broadway Hotel & Conference Center and Actinium's presentation will be delivered at 8:30 am ET in Room 302/303. Management will be available for 1-on-1 meetings with conference attendees. To schedule a meeting with management contact Steve O'Loughlin, Vice President, Finance and Corporate Development at soloughlin@actiniumpharma.com.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact Information